Ph II Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head and Neck Cancer

Trial Profile

Ph II Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head and Neck Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Gefitinib (Primary) ; Carboplatin; Fluorouracil; Hydroxycarbamide; Paclitaxel
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.
    • 05 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Aug 2017.
    • 29 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top